Fast Company’s 11th annual Innovation Festival takes over New York City this September 15–18. Though every year introduces new offerings to the Innovation Festival, we’re also bringing back an ...
JSKN003 has shown a 63% objective response rate and 7.7 months median progression-free survival in PROC patients, with higher efficacy in HER2-positive subgroups. The FDA's fast track designation ...
A phase 2 trial evaluating CS-1103 in participants with methamphetamine use disorder is expected to begin in the first quarter of 2026. The Food and Drug Administration (FDA) has granted Fast Track ...
On Thursday, the U.S. Food and Drug Administration (FDA) announced six additional awardees under the Commissioner's National Priority Voucher (CNPV) pilot program. The second cohort brings the total ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. ADX-2191 is an intravitreal formulation of methotrexate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback